Navigation Links
Yeast Model Shows Promise as Alzheimer's Test

A century ago this month, German psychiatrist Alois Alzheimer formally described characteristics of the neurodegenerative disease //which ultimately came to bear his name. While international efforts to learn about Alzheimer's disease and develop treatments have progressed significantly in recent years, a cure remains an elusive goal.

A new research tool developed by Susan Liebman, distinguished university professor of biological sciences at the University of Illinois at Chicago, may ultimately provide a means for treating the earliest stage of Alzheimer's, thereby stemming its progression.

Alzheimer's disease is characterized by the formation of plaques in the brain largely composed of fibers made from a peptide called beta-amyloid, or A-beta, for short. There is abundant evidence to support the hypothesis that accumulation of A-beta peptide triggers the appearance of Alzheimer's. But while earlier research suggested the A-beta fiber caused Alzheimer's, recent research points at much smaller aggregates of the peptide as the culprit.

"We've developed a yeast model system in which A-beta small aggregate formation can be detected," said Liebman. "The system employs a fusion of the human A-beta peptide to a functional yeast protein, called a reporter protein, which is only active in allowing cells to grow on test media if the fusion does not form aggregates."

Liebman said the yeast model system can be used to develop a high throughput assay to screen small molecules to find those that inhibit the A-beta dependent aggregation. "We'll screen a library of drugs and compounds, looking for ones that allow our yeast with the reporter protein to grow."

She said after the assay conditions are perfected, the screen will be ready for an automated process that will allow for fast testing of many compounds. Medicinal chemists would then study the structures of compounds that pass the screen and design compounds that en hance the activity without being toxic. Animal and human trials would follow.

"One promising, emerging approach for treatment of Alzheimer's disease is to prevent these smaller aggregates from forming," said Liebman. "Disruption of these small aggregates rather than the larger fibers seems prudent since inhibition of A-beta fiber formation might cause the smaller aggregate species to accumulate, and since inhibiting smaller aggregate formation should also prevent the initial formation of the fibers."

Source-Newswise
'"/>




Related medicine news :

1. Yeast Genome Unravels Genes Critical For Maintaining DNA Integrity
2. Chinese Red Yeast Rice Lowers Lipid Levels
3. From a Lowly Yeast, Researchers Divine a Clue to Human Disease
4. Primitive Yeast Yields Secrets Of Human Cholesterol And Drug Metabolism
5. Vitamin Extends Life in Yeast, Dartmouth Medical School Researchers Find
6. Researchers Develop Mouse Model Of Brain Tumor
7. New Model for understanding Tumor Metastasis
8. Mathematical Model Can Now Help Predict Asthma Risk
9. Model Kate Moss - Re-Birth After Humiliation
10. Womens Self-Esteem Not Lowered By Seeing Ultra Thin Models
11. India Can Become A Role Model In Combating HIV Infections
Post Your Comments:
*Name:
*Comment:
*Email:


(Date:12/5/2016)... ... December 05, 2016 , ... ... at the 2016 Anti-Aging & Beauty Awards at The Aesthetic & Anti-aging ... Anti-aging Medicine European Congress (AMEC) brings together the industry’s leading scientific experts, ...
(Date:12/5/2016)... Columbus, OH (PRWEB) , ... December 05, 2016 ... ... novel engineering solution called the CardioQuick Patch® significantly improves the reproducibility and accuracy ... usability in various healthcare settings. , Over the last 60 years, studies ...
(Date:12/4/2016)... York, NY (PRWEB) , ... December 03, 2016 ... ... largest non-profit organization devoted exclusively to funding innovative lymphoma research and serving the ... services – hosted its first Swirl: A Wine Tasting Event in New York ...
(Date:12/4/2016)... ... December 03, 2016 , ... While James Earl Jones is known ... for in a show called "Front Page". One of the forthcoming episodes examines mammogram ... rates have plummeted in large part due to early detection. Like any other disease, ...
(Date:12/4/2016)... ... December 03, 2016 , ... ... Entrepreneurial Company in the Dallas area” Tuesday evening at the 26th Annual SMU ... presented by SMU's Cox School’s Caruth Institute for Entrepreneurship. Dallas 100™, co-founded by ...
Breaking Medicine News(10 mins):
(Date:12/4/2016)... 2016   Pairnomix, LLC, a genetic research company ... by the White House, today announced that findings from its ... of candidate therapies for a patient with epileptic encephalopathy caused ... presented at the 70 th Annual Meeting of the ... , December 2-6, 2016.  Pairnomix, unique process ...
(Date:12/4/2016)... , Dec. 3, 2016  Findings from ... safety of CTL019, an investigational chimeric antigen receptor ... pediatric and young adult patients with B-cell acute ... an oral session at the 58th American Society ... 3, 4:00-5:30 p.m.). The global Phase II study ...
(Date:12/2/2016)... British Columbia , December 2, 2016 bioLytical Laboratories, ... de la Compañía, el INSTI HIV Self Test , a los miembros ... ... INSTI HIV Self Test! (PRNewsFoto/bioLytical Laboratories) ...      (Photo: http://photos.prnewswire.com/prnh/20161201/444905 ) ...
Breaking Medicine Technology: